We are live on ! Find out more
EA

Emerald Advisers Portfolio holdings

AUM $3.16B
1-Year Est. Return 109.58%
This Fund
S&P 500
This Quarter Est. Return
+11.43%
1 Year Est. Return
+109.58%
3 Year Est. Return
+352.93%
5 Year Est. Return
+451.34%
10 Year Est. Return
+3,577.15%
AUM
$2.59B
AUM Growth
+$202M
Cap. Flow
+$46.2M
Cap. Flow %
1.79%
Top 10 Hldgs %
21.22%
Holding
269
New
22
Increased
94
Reduced
105
Closed
21

Top Sells

Rank Stock Value
1
TMDX icon
Transmedics
TMDX
+$26.6M
2
FTAI icon
FTAI Aviation
FTAI
+$22.8M
3
CRS icon
Carpenter Technology
CRS
+$19.1M
4
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$17.8M
5
VAL icon
Valaris
VAL
+$16.7M

Sector Composition

Rank Sector Weight
1 Technology 24.96%
2 Healthcare 24.88%
3 Industrials 21.18%
4 Financials 12%
5 Consumer Discretionary 6.13%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
MSFT icon
101
Microsoft
MSFT
$2.93T
$7.83M 0.3%
18,200
UTZ icon
102
Utz Brands
UTZ
$638M
$7.79M 0.3%
440,096
-312,861
-42% -$5.2M
SPT icon
103
Sprout Social
SPT
$518M
$7.65M 0.3%
263,041
+141,252
+116% +$4.6M
AAOI icon
104
Applied Optoelectronics
AAOI
$8.22B
$7.53M 0.29%
526,458
+13,737
+3% +$142K
IMVT icon
105
Immunovant
IMVT
$8.27B
$7.13M 0.28%
250,039
-38,525
-13% -$1.14M
AAPL icon
106
Apple
AAPL
$4.9T
$7.01M 0.27%
30,075
+1,735
+6% +$387K
BOW
107
Bowhead Specialty Holdings
BOW
$1.01B
$6.8M 0.26%
242,633
+7,683
+3% +$215K
BIOA
108
BioAge Labs
BIOA
$1.01B
$5.85M 0.23%
+281,317
New +$5.64M
MDGL icon
109
Madrigal Pharmaceuticals
MDGL
$12.8B
$5.79M 0.22%
27,265
-69,499
-72% -$17.8M
STC icon
110
Stewart Information Services
STC
$2.19B
$5.33M 0.21%
+71,318
New +$5.04M
TARS icon
111
Tarsus Pharmaceuticals
TARS
$2.61B
$4.81M 0.19%
+146,298
New +$4.11M
FLYW icon
112
Flywire
FLYW
$2.24B
$4.75M 0.18%
289,825
-63,745
-18% -$1.11M
AMZN icon
113
Amazon
AMZN
$2.66T
$4.48M 0.17%
24,029
+1,679
+8% +$306K
IBTA icon
114
Ibotta
IBTA
$734M
$4.05M 0.16%
65,733
+31,166
+90% +$1.89M
ATEC icon
115
Alphatec Holdings
ATEC
$1.31B
$3.81M 0.15%
685,447
-336,078
-33% -$2.58M
GOOGL icon
116
Alphabet (Google) Class A
GOOGL
$4.23T
$3.6M 0.14%
21,699
CVRX icon
117
CVRx
CVRX
$130M
$3.55M 0.14%
403,054
-49,505
-11% -$450K
META icon
118
Meta Platforms (Facebook)
META
$1.64T
$3.18M 0.12%
5,561
CCNE icon
119
CNB Financial Corp
CCNE
$1.02B
$2.5M 0.1%
103,969
-40,000
-28% -$932K
AVGO icon
120
Broadcom
AVGO
$1.76T
$2.19M 0.08%
12,670
LNG icon
121
Cheniere Energy
LNG
$55B
$1.9M 0.07%
10,560
-136
-1% -$24.5K
IRWD icon
122
Ironwood Pharmaceuticals
IRWD
$635M
$1.88M 0.07%
456,770
-329,567
-42% -$1.77M
LLY icon
123
Eli Lilly
LLY
$1.05T
$1.66M 0.06%
1,873
+804
+75% +$723K
MDB icon
124
MongoDB
MDB
$25.1B
$1.65M 0.06%
6,101
-1,290
-17% -$335K
TEVA icon
125
Teva Pharmaceuticals
TEVA
$37.3B
$1.54M 0.06%
85,559
-1,188
-1% -$20.8K

Similar funds

Emerald Advisers's Q3 2024 Portfolio in Review

As of Q3 2024, Emerald Advisers held 269 positions worth $2.59B, up 8.5% from $2.38B the previous quarter. Its ten largest holdings account for 21% of the portfolio.

Emerald Advisers's Q3 2024 filing shows 22 new, 94 increased, 105 reduced and 21 closed positions. Its largest new stake was Avid Bioservices, Inc. Common Stock: 1,448,916 shares worth $16.5M. The largest sale was Transmedics, an estimated $26.6M.

By sector, the portfolio is most concentrated in Technology at 25% of assets, up from 25% a quarter earlier, followed by Healthcare and Industrials.

  • Emerald Advisers's largest Q3 2024 buy was Avid Bioservices, Inc. Common Stock: 1,448,916 shares worth $16.5M.
  • Emerald Advisers added most to Fulton Financial in Q3 2024, an estimated $16.2M increase.
  • Emerald Advisers's biggest Q3 2024 reduction was Transmedics, cutting an estimated $26.6M.
  • Emerald Advisers fully exited Savers in Q3 2024, selling an estimated $9.16M.
  • Emerald Advisers's ten largest holdings make up 21% of its $2.59B portfolio in Q3 2024.
  • Emerald Advisers opened 22 new positions and closed 21 in Q3 2024.
  • Emerald Advisers's portfolio value rose 8.5% quarter-over-quarter to $2.59B.

Based on Emerald Advisers's 13F filing for Q3 2024, filed 29 Oct 2024.